Bio-Path Holdings develops RNAi nano particle drugs for clinical and preclinical oncology stages using its patented DNA modification technology. Their lead drug candidate, prexigebersen, is currently undergoing Phase II clinical trials for the treatment of AML and myelodysplastic syndrome. Other products in development include Liposomal Bcl-2 and Liposomal STAT3 for the treatment of lymphoma and various types of cancer.